z-logo
open-access-imgOpen Access
Re-imagining the future of diagnosis of Neglected Tropical Diseases
Author(s) -
Rosanna W. Peeling,
Debrah I. Boeras,
John N. Nkengasong
Publication year - 2017
Publication title -
computational and structural biotechnology journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.908
H-Index - 45
ISSN - 2001-0370
DOI - 10.1016/j.csbj.2017.02.003
Subject(s) - neglected tropical diseases , leverage (statistics) , diagnostic test , psychological intervention , multiplex , risk analysis (engineering) , medicine , computer science , public health , business , environmental health , pathology , artificial intelligence , bioinformatics , pediatrics , psychiatry , biology
Neglected Tropical Diseases (NTDs) affect an estimated 1 billion people in 149 countries. The World Health Organization (WHO) prioritised 17 NTDs for control and elimination by 2020 and defined a Road Map to help countries reach these goals. Improved diagnostics for NTDs are essential for guiding treatment strategies at different thresholds of control, interruption of transmission, elimination and post-elimination surveillance. While substantial progress has been made in the last decade with chemotherapy, the same cannot be said of diagnostics, largely due to the perceived lack of a commercially viable market for NTD diagnostics. New sample in-answer out nucleic acid amplification technologies that can be performed at the point-of-care offer improved performance over current technologies and the potential to test for multiple pathogens using a single specimen. Finding commonalities for different NTDs in terms of geographic overlap, sentinel populations and treatment strategy will allow NTD programs to leverage these innovations to build cost-effective multiplex surveillance platforms. Connectivity solutions linking data from diagnostic laboratories and POC test readers/devices provide opportunities for automated surveillance systems to make health systems more efficient, improving patient outcomes and assessing impact of interventions in real time. New models of public-private product development partnerships are critical in leveraging diagnostic innovation in other priority area for better diagnosis, control and elimination of NTDs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom